144 related articles for article (PubMed ID: 26412158)
21. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
[TBL] [Abstract][Full Text] [Related]
22. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
23. Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation.
Occhi G; Regazzo D; Albiger NM; Ceccato F; Ferasin S; Scanarini M; Denaro L; Cosma C; Plebani M; Cassarino MF; Mantovani G; Stalla GK; Pecori Giraldi F; Paez-Pareda M; Scaroni C
Endocrinology; 2014 Sep; 155(9):3538-49. PubMed ID: 24926820
[TBL] [Abstract][Full Text] [Related]
24. The genomic profiling and MAMLD1 expression in human and canines with Cushing's disease.
Wang A; Neill SG; Newman S; Tryfonidou MA; Ioachimescu A; Rossi MR; Meij BP; Oyesiku NM
BMC Endocr Disord; 2021 Sep; 21(1):185. PubMed ID: 34517852
[TBL] [Abstract][Full Text] [Related]
25. Driver mutations in USP8 wild-type Cushing's disease.
Sbiera S; Perez-Rivas LG; Taranets L; Weigand I; Flitsch J; Graf E; Monoranu CM; Saeger W; Hagel C; Honegger J; Assie G; Hermus AR; Stalla GK; Herterich S; Ronchi CL; Deutschbein T; Reincke M; Strom TM; Popov N; Theodoropoulou M; Fassnacht M
Neuro Oncol; 2019 Oct; 21(10):1273-1283. PubMed ID: 31222332
[TBL] [Abstract][Full Text] [Related]
26. Paediatric Cushing's disease - a literature review of epidemiology, pathogenesis, clinical symptoms, and diagnostics.
Pasternak-Pietrzak K; Moszczyńska E; Jurkiewicz E; Szalecki M
Endokrynol Pol; 2020; 71(1):87-95. PubMed ID: 32129467
[TBL] [Abstract][Full Text] [Related]
27. Identification of recurrent USP48 and BRAF mutations in Cushing's disease.
Chen J; Jian X; Deng S; Ma Z; Shou X; Shen Y; Zhang Q; Song Z; Li Z; Peng H; Peng C; Chen M; Luo C; Zhao D; Ye Z; Shen M; Zhang Y; Zhou J; Fahira A; Wang Y; Li S; Zhang Z; Ye H; Li Y; Shen J; Chen H; Tang F; Yao Z; Shi Z; Chen C; Xie L; Wang Y; Fu C; Mao Y; Zhou L; Gao D; Yan H; Zhao Y; Huang C; Shi Y
Nat Commun; 2018 Aug; 9(1):3171. PubMed ID: 30093687
[TBL] [Abstract][Full Text] [Related]
28. PPAR-gamma in Cushing's disease.
Heaney AP
Pituitary; 2004; 7(4):265-9. PubMed ID: 16416039
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Iino K; Oki Y; Matsushita F; Yamashita M; Hayashi C; Miura K; Nishizawa S; Nakamura H
Pituitary; 2007; 10(1):35-45. PubMed ID: 17410413
[TBL] [Abstract][Full Text] [Related]
30. Genetics of Cushing's syndrome.
Yaneva M; Vandeva S; Zacharieva S; Daly AF; Beckers A
Neuroendocrinology; 2010; 92 Suppl 1():6-10. PubMed ID: 20829611
[TBL] [Abstract][Full Text] [Related]
31. An approach to the evaluation and treatment of Cushing's disease.
Brown RL; Weiss RE
Expert Rev Anticancer Ther; 2006 Sep; 6 Suppl 9():S37-46. PubMed ID: 17004856
[TBL] [Abstract][Full Text] [Related]
32. USP8, USP48, and BRAF mutations differ in their genotype-phenotype correlation in Asian Indian patients with Cushing's disease.
Abraham AP; Pai R; Beno DL; Chacko G; Asha HS; Rajaratnam S; Kapoor N; Thomas N; Chacko AG
Endocrine; 2022 Feb; 75(2):549-559. PubMed ID: 34664215
[TBL] [Abstract][Full Text] [Related]
33. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
34. Genomics in Cushing's Disease: The Dawn of a New Era.
Reincke M; Theodoropoulou M
J Clin Endocrinol Metab; 2021 May; 106(6):e2455-e2456. PubMed ID: 33524136
[No Abstract] [Full Text] [Related]
35. USP8 mutation in Cushing's disease.
Huang C; Shi Y; Zhao Y
Oncotarget; 2015 Jul; 6(21):18240-1. PubMed ID: 26285834
[No Abstract] [Full Text] [Related]
36. Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas.
Tani Y; Inoshita N; Sugiyama T; Kato M; Yamada S; Shichiri M; Hirata Y
Eur J Endocrinol; 2010 Oct; 163(4):523-9. PubMed ID: 20616110
[TBL] [Abstract][Full Text] [Related]
37. Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.
Smith TR; Hulou MM; Huang KT; Nery B; de Moura SM; Cote DJ; Laws ER
Neurosurg Focus; 2015 Feb; 38(2):E12. PubMed ID: 25639314
[TBL] [Abstract][Full Text] [Related]
38. Gene mutations in Cushing's disease.
Xiong Q; Ge W
Biomed Rep; 2016 Sep; 5(3):277-282. PubMed ID: 27588171
[TBL] [Abstract][Full Text] [Related]
39. Genetics of Cushing's disease.
Simon J; Theodoropoulou M
J Neuroendocrinol; 2022 Aug; 34(8):e13148. PubMed ID: 35596671
[TBL] [Abstract][Full Text] [Related]
40. Cushing's disease.
Tritos NA; Biller BM
Handb Clin Neurol; 2014; 124():221-34. PubMed ID: 25248590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
